How should I manage a patient with recurrent buccal mucosa carcinoma who presents with pain, hyperglycemia (blood glucose 11.9 mmol/L), leukocytosis (white blood cell count 11,400) with neutrophilia (90%) and lymphopenia (7%)?

Management of Recurrent Buccal Mucosa Carcinoma with Pain and Systemic Findings

This patient with recurrent buccal mucosa carcinoma must be urgently referred to a tertiary cancer center for multidisciplinary team evaluation to determine if salvage surgery or re-irradiation is feasible; if not amenable to curative locoregional treatment, systemic therapy should be initiated based on PD-L1 status and prior platinum exposure, while simultaneously addressing the pain, hyperglycemia, and possible infection or paraneoplastic leukemoid reaction. 1

Immediate Assessment Priorities

Evaluate for Curative vs Palliative Intent

• First determine resectability: Patients with locoregional recurrence should be discussed within a multidisciplinary team at a reference tertiary center to assess possibility of salvage surgery or re-irradiation in selected cases 1
• The laboratory findings (leukocytosis with neutrophilia and lymphopenia) require urgent clarification of etiology before proceeding

Address the Laboratory Abnormalities

Leukocytosis (WBC 11,400 with 90% neutrophils, 7% lymphocytes):

• This pattern suggests three possibilities that must be differentiated:

  1. Infection - most common with neutrophilia
  2. Paraneoplastic leukemoid reaction - associated with advanced squamous cell carcinoma and carries extremely poor prognosis 2
  3. Glucocorticoid effect - if patient received steroids for pain/inflammation 3

• True paraneoplastic leukemoid reaction typically presents with WBC ≥50,000 cells/µL and indicates aggressive disease with very poor outcomes 2

• Your patient's WBC of 11,400 is more consistent with infection or stress response

• Action: Obtain blood cultures, chest imaging, and examine for infection sources before attributing to paraneoplastic syndrome

Hyperglycemia (blood glucose 11.9 mmol/L = 214 mg/dL):

• Cancer patients frequently develop hyperglycemia from multiple mechanisms 4, 3
• If patient received glucocorticoids for symptom management, this is the likely cause 3
• Hyperglycemia in cancer patients is associated with increased infections, treatment delays, and higher mortality 4
• Action: Check HbA1c for baseline assessment; initiate insulin therapy if moderate-severe hyperglycemia, especially if glucocorticoid-induced 3

Systemic Treatment Algorithm (If Not Amenable to Curative Locoregional Treatment)

The treatment selection depends on three key factors 1:

1. If NO platinum-based chemotherapy in last 6 months:

PD-L1 Testing is Critical:

• If PD-L1 positive (CPS ≥1):

  • Pembrolizumab monotherapy [Level I, A evidence] - especially appropriate when rapid tumor shrinkage is not urgently needed 1
  • Median OS: 12.3-14.9 months depending on CPS score
  • Better tolerated (grade 3-5 adverse events 54.7% vs 83.3% with chemotherapy)

• If PD-L1 negative OR symptomatic patient needing rapid response:

  • Pembrolizumab + platinum (cisplatin or carboplatin) + 5-FU [Level I, A evidence] 1
  • Median OS: 13 months
  • Superior to EXTREME regimen (platinum/5-FU/cetuximab)
  • This combination works regardless of PD-L1 status

2. If platinum-based chemotherapy within last 6 months AND immunotherapy-naïve:

• Platinum/5-FU/cetuximab (EXTREME regimen) [Level I, A evidence] 1

3. If previously treated with both platinum and immunotherapy:

• Nivolumab or pembrolizumab [Level I, A evidence] 1
• Alternative: Taxane, methotrexate, or cetuximab with best supportive care 1

Pain Management Strategy

For oral cavity cancer pain with recurrence:

Multimodal Analgesia

• Opioids remain cornerstone for moderate-severe cancer pain
• Gabapentin may be added for neuropathic component, though evidence is mixed for mucositis pain 5
• Avoid relying solely on "magic mouthwash" - compositions vary widely and evidence is inconsistent 5

Local Measures

• Bland mouth rinses with sodium bicarbonate 5
• Benzydamine oral rinse has supporting data for mucositis-related pain 5
• Topical lidocaine gel or liquid for localized pain 5

Consider Interventional Options

• If pain is refractory, consult pain/palliative care specialist for interventional approaches 5
• Radiation therapy can provide palliative benefit for symptomatic locoregional disease 1

Critical Pitfalls to Avoid

1. Do not delay referral to tertiary center - salvage surgery outcomes are better with early-stage recurrence and good performance status 1

2. Do not assume leukocytosis is paraneoplastic without excluding infection - true paraneoplastic leukemoid reaction requires WBC ≥50,000 and is diagnosis of exclusion 2

3. Do not ignore hyperglycemia - it increases infection risk and mortality; requires active management 4, 3

4. Do not use pembrolizumab monotherapy in PD-L1 negative patients - insufficient evidence for survival benefit 1

5. Do not use pembrolizumab monotherapy if rapid tumor response is needed - PFS and response rates are inferior to combination therapy (ORR 19-23% vs 36% with chemotherapy combinations) 1

6. Lymphopenia (7%) may indicate immunosuppression - consider infection risk carefully and may impact immunotherapy response

Immediate Action Plan

1. Urgent MDT referral to assess salvage surgery/re-irradiation feasibility
2. Rule out infection - blood cultures, imaging, clinical examination
3. Control hyperglycemia - insulin therapy if needed
4. Optimize pain control - opioids + adjuvants + local measures
5. Obtain PD-L1 testing if not already done
6. Clarify prior treatment history - platinum exposure timing, prior immunotherapy
7. Assess performance status - critical for treatment selection